Skip to main content

Sirris and Coris combine biotechnology and microfabrication

In late 2015, Coris BioConcept launched a new, fully-automated medical diagnostic platform – a sort of portable laboratory no bigger than an office computer. The sample taken from the patient is entered into the device on various fluidic chips depending on the types of analysis to be conducted. Coris called on Sirris's expertise in microfabrication to develop the biomedical analysis chip, which has microchannels measuring a fraction of a millimetre.
  • Coris BioConcept has developed a medical diagnostic platform based on fluidic chips.
  • Sirris created an extremely precise micro-mould to produce the chip prototype and pre-production models. 
  • This new diagnostic platform was presented to the public in late 2015. 

Coris Bioconcept designs, produces and markets rapid diagnostic kits for gastrointestinal and respiratory diseases. The SME was established in 1996 and over two decades it has developed a range of more than 30 tests. Based in Gembloux, Coris BioConcept distributes its products to health professionals in over 60 countries.

“To manufacture the fluidic chip, we had to create a mould with many microscopic details on a surface that needed to comply with strict appearance and roughness specifications.”

Microfluidic chip

The new diagnostic platform developed by Coris BioConcept aims to identify multiple parameters simultaneously from a single sample, under tightly controlled conditions. The sample to be analysed is placed on a microfluidic chip (lab-on-a-chip). To develop this chip, Coris BioConcept called on Sirris and its expertise in microfabrication (SMALL Lab).

Submillimetre details and submicrometre surface roughness 

Sirris helped to create prototypes of the fluidic chip designed by Coris BioConcept, then the pre-production models used to test and validate the system. For this purpose, Sirris's Microfabrication Application Lab (SMALL) created a mould to a set of specifications never before achieved by Sirris, with details measuring a fraction of a millimetre and submicrometre surface roughness. Another Belgian company, Wow Technology, contributed its expertise to develop the actual platform. 

Faster, more reliable tests 

The new diagnostic platform will be brought to market in late 2016. In under one hour, it will be able to identify the bacteria causing septicaemia and how resistant they are to antibiotics. Test conditions are also better controlled than in a laboratory, resulting in increased reliability. The speed and reliability of the diagnosis mean that the patient can receive the appropriate treatment more quickly.